Academic Journal
589 RUBY trial post hoc analysis of number needed to treat and incremental costs per outcome of dostarlimab + carboplatin-paclitaxel (CP) vs placebo + CP for primary advanced/recurrent endometrial cancer
| العنوان: | 589 RUBY trial post hoc analysis of number needed to treat and incremental costs per outcome of dostarlimab + carboplatin-paclitaxel (CP) vs placebo + CP for primary advanced/recurrent endometrial cancer |
|---|---|
| المؤلفون: | Llenalia Garcia-Fernandez, Jean Hurteau, Lydia Lee, Solomon J Lubinga, Tilman Payer, Meghann Gregg, Odette Allonby |
| المصدر: | Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023) |
| بيانات النشر: | BMJ Publishing Group |
| سنة النشر: | 2023 |
| المجموعة: | Directory of Open Access Journals: DOAJ Articles |
| مصطلحات موضوعية: | Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 2051-1426 |
| Relation: | https://doaj.org/toc/2051-1426; https://doaj.org/article/63cf195830b644f8b2b54e1dcbe0ad1b |
| DOI: | 10.1136/jitc-2023-SITC2023.0589 |
| الاتاحة: | https://doi.org/10.1136/jitc-2023-SITC2023.0589 https://doaj.org/article/63cf195830b644f8b2b54e1dcbe0ad1b |
| رقم الانضمام: | edsbas.48A1D17 |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 20511426 |
|---|---|
| DOI: | 10.1136/jitc-2023-SITC2023.0589 |